GLG News by Managed Care Reimbursement Experts

Joe AtkinsChief Executive OfficerMedical Concepts & Innovations

FDA Restrictions on ESA's Will Have Minimal Effect of EPO Usage.

August 4, 2008

Analysis of:Amgen Told to Reword Drug Label | www.nytimes.com

1)  Concerns over the new FDA restrictions on ESA's is being overstated. 2)  Amgen will continue to do well in the ESA market place, in spite of these changes. 3)  J&J will receive the brunt of these changes, strictly because of their market concentration in the oncology market. 4)  Amgen will continue on as the "King of US ESA's".

Joe AtkinsChief Executive OfficerMedical Concepts & Innovations

Veterans Admininstration Sets The Standard for Electronic Medical Records: Why Re-invent The Wheel?

August 4, 2008

Analysis of:Nationwide EHR Implementation Price Tag Estimated at $150 billion | www.govhealthit.com

The VA has already won many awards for an electronic medical records system, which tax payers have already paid for. Adopting the VA "CPRS" program would save the taxpayers and the private sector hundreds of billions of dollars.

Richard AmerlingAssociate Professor of Clinical MedicineAlbert Einstein College of Medicine

The Dark Side of Fosamax

July 25, 2008

Analysis of:Drugs to Build Bones May Weaken Them | www.nytimes.com

Considering the effects of fosamax and other bisphosphonates on bone remodeling, it is not at all surprising to see problems arising with the long term use of these agents.  

Richard AmerlingAssociate Professor of Clinical MedicineAlbert Einstein College of Medicine

So Much for Health "Insurance"

July 10, 2008

Analysis of:Pricey Drugs Put Squeeze on Doctors | online.wsj.com

It's intresting that nowhere in this article was the topic of true insurance for catastrophic illness brought up.  The problem with our current health insurance market is that for most it is pre-paid care, not insurance against a rare, but catastrophic, event. 

Richard AmerlingAssociate Professor of Clinical MedicineAlbert Einstein College of Medicine

Our Kids on Statins...........Not!

July 10, 2008

Analysis of:8-Year-Olds on Statins? A New Plan Quickly Bites Back | www.nytimes.com

With the pipeline for new drugs running dry, it is no surprise that pharmaceutical companies are looking to expand indications for existing products still under patent protection.  What better way to do this than by creating entirely new patient populations out of whole cloth?

Jack RubinMedical Director and Chief Executive Officer Los Angeles Vascular Center

Tekturan losers blood pressure and proteinuria simultaneously

May 27, 2008

Analysis of:New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone | www.novartis.com

While no more would argue that control of systolic hypertension is crucial to preventing the consequences of hypertension such as congestive heart failure, MI's, left ventricular hyperthrophy, stroke and kidney failure there are other factors that are associated with these disease states. One of these is proteinuria.

Joe AtkinsChief Executive OfficerMedical Concepts & Innovations

FDA: Chinese Manufacturer of Tainted Heparin Involved in Fraud.

April 30, 2008

Analysis of:UPDATE: FDA Head Sees Economic Fraud Behind Tainted Heparin | www.reuters.com

First, and foremost, the only working link for this article can be found at: http://www.reuters.com/article/domesticNews/idUSWAT00934620080415?feedType=RSS&feedName=domesticNews Although there is no proof offered in the article to substantiate the suggestion of fraud, there is enough circumstantial evidence to suggest that it is so.

Joe AtkinsChief Executive OfficerMedical Concepts & Innovations

FDA Fees Must Be Increased to Fund Inspection of Chinese Products.

April 30, 2008

Analysis of:FDA fees eyed to boost food, drug safety | www.usatoday.com

One only has to read about the Heparin debacle, which has killed, at least, 81 Americans, to realize that there is a serious issue with the quality of medicines produced in China.  Manufacturing of medical food and consumer goods in China is growing at such a rate, the Chinese government has neither the resources or the will to maintain adequate inspection of quality control.  The only way it's going to be done is if our FDA becomes involved, hence the increase in FDA fees.

Joe AtkinsChief Executive OfficerMedical Concepts & Innovations

Who to Blame for Waste in the Medical Industry? Who's on First?

April 30, 2008

Analysis of:The Price of Excess: Identifying Waste in Healthcare Spending | blogs.wsj.com

It's easy to point fingers of blame and this article does that, very well.  According to the "annalysis" everybody is to blame.  And, they're right, everyone is to blame, but where the article fails is the authoris inability to point out a real solution to the problem of wasted dollars spent on the American healthcare system.

Joe AtkinsChief Executive OfficerMedical Concepts & Innovations

Anemia Drugs Have Been Abused for Profit!

April 30, 2008

Analysis of:WellPoint likely to follow FDA on anemia drugs | www.reuters.com

Over the last year, it has become clear that the over-use of anemia drugs for cancer and renal failure has become a problem.  The reason can be sumed up in one word, which is profit.

Page : 123Next1 to 10 of 21